In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron by Ye-Fan Hu, Jing-Chu Hu, Hin Chu, Thomas Yau, Bao-Zhong Zhang, Jian-Dong Huang

Get full text

Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review by Arndt Vogel, Robin Kate Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa

Get full text

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040) by Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras

Get full text

Adverse events associated with the delivery of telerehabilitation: A scoping review protocol. by Thomas Yau, McKyla McIntyre, Josh Chan, Damanveer Bhogal, Angie Andreoli, Mark Bayley, Carl Froilan D Leochico, Ailene Kua, Meiqi Guo, Sarah Munce

Get full text

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC by Yawen Dong, Jeffrey Sum Lung Wong, Ryohichi Sugimura, Ka-On Lam, Bryan Li, Gerry Gin Wai Kwok, Roland Leung, Joanne Wing Yan Chiu, Tan To Cheung, Thomas Yau

Get full text

First-line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis by Khi Yung Fong, Joseph Jonathan Zhao, Rehena Sultana, Joycelyn Jie Xin Lee, Suat Ying Lee, Stephen Lam Chan, Thomas Yau, David Wai Meng Tai, Raghav Sundar, Chow Wei Too

Get full text

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial by Masatoshi Kudo, Ho Yeong Lim, Ann-Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, Naoki Morimoto, Kazuyoshi Ohkawa, Tatsuya Yamashita, Kyung-Hun Lee, Erluo Chen, Abby B. Siegel, Baek-Yeol Ryoo

Get full text

A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma by Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L. Chan

Get full text

ALBI score and outcomes in patients with hepatocellular carcinoma: analysis of the randomized controlled trial KEYNOTE-240 by Arndt Vogel, Philippe Merle, Chris Verslype, Richard S. Finn, Andrew X. Zhu, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Baek-Yeol Ryoo, Jennifer Knox, Bruno Daniele, Shukui Qin, Ziwen Wei, Yanna Miteva, Usha Malhotra, Abby B. Siegel, Masatoshi Kudo

Get full text

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study by Jeffrey Sum-Lung Wong, Yawen Dong, Vikki Tang, Thomas Leung, Cynthia S. Y. Yeung, Anna Tai, Ada Law, Tracy Shum, Gerry Gin-Wai Kwok, Bryan Cho-Wing Li, Roland Leung, Joanne Chiu, Ka-Wing Ma, Wong-Hoi She, Josephine Tsang, Tan-To Cheung, Thomas Yau

Get full text

Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma by Benjamin Koh, Darren Jun Hao Tan, Wen Hui Lim, Jeffrey S L Wong, Cheng Han Ng, Kai En Chan, Meng Wang, Wei Peng Yong, Yock Young Dan, Louis Z Wang, Nigel Tan, Mark Muthiah, Alfred Kow, Nicholas L. Syn, Daniel Q. Huang, Thomas Yau

Get full text

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors by Thomas Yau, Ignacio Garrido-Laguna, Pierre-Eric Juif, Markus Joerger, Anna Spreafico, Todd M Bauer, Chia-Chi Lin, Armando Santoro, Richard Greil, Helen Evans, Marc Pelletier, Toshikiko Doi, Maria-Elisabeth Goebeler, Viviana Cremasco, Marie Luise Hütter-Krönke, Antonella Perotti, Darlene Lu, Louise Barys, Claire Fabre

Get full text

Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants by Ye-Fan Hu, Ye-Fan Hu, Jing-Chu Hu, Hua-Rui Gong, Antoine Danchin, Antoine Danchin, Ren Sun, Hin Chu, Ivan Fan-Ngai Hung, Kwok Yung Yuen, Kelvin Kai-Wang To, Bao-Zhong Zhang, Thomas Yau, Jian-Dong Huang, Jian-Dong Huang, Jian-Dong Huang

Get full text

Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma After First-Line Therapy: Expert Recommendations from Hong Kong, Singapore and Taiwan by Thomas Yau, David Tai, Stephen Lam Chan, Yi-Hsiang Huang, Su Pin Choo, Chiun Hsu, Tan To Cheung, Shi-Ming Lin, Wei Peng Yong, Joycelyn Lee, Thomas Leung, Tracy Shum, Cynthia S. Y. Yeung, Anna Yin-Ping Tai, Ada Lai Yau Law, Ann-Lii Cheng, Li-Tzong Chen

Get full text

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial by Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn

Get full text

Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-analysis of Randomized Trials by Darren Jun Hao Tan, Ansel Shao Pin Tang, Wen Hui Lim, Cheng Han Ng, Benjamin Nah, Clarissa Fu, Jieling Xiao, Benjamin Koh, Phoebe Wen Lin Tay, Eunice X Tan, Margaret Teng, Nicholas Syn, Mark D Muthiah, Nobuharu Tamaki, Sung Won Lee, Beom Kyung Kim, Thomas Yau, Arndt Vogel, Rohit Loomba, Daniel Q. Huang

Get full text

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma by Amaia Lujambio, Thomas Yau, Lipika Goyal, Andrew X Zhu, Ignacio Melero, Tim F Greten, Ann-Lii Cheng, Bruno Sangro, David J Pinato, Peter R Galle, Ghassan K Abou-Alfa, Austin G Duffy, Anthony B. El-Khoueiry, Richard S Finn, Aiwu Ruth He, Ahmed O Kaseb, Robin Kate Kelley, Riccardo Lencioni, Donna Mabry Hrones, Roberto I Troisi, Andrea Wilson Woods

Get full text

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors by Stephen L. Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean-Frederic Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Eric Assenat, Andrew X. Zhu, Thomas Yau, Ho Yeong Lim, Jordi Bruix, Andreas Geier, Carmen Guillén-Ponce, Angelica Fasolo, Richard S. Finn, Jia Fan, Arndt Vogel, Shukui Qin, Markus Riester, Vasiliki Katsanou, Monica Chaudhari, Tomoyuki Kakizume, Yi Gu, Diana Graus Porta, Andrea Myers, Jean-Pierre Delord

Get full text